Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.56 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.56 |
| ▸ | FABP3 | P05413 | 6/20 | 0.57 |
| ▸ | TERT | O14746 | 3/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.56 |
| ▸ | PPARG | P37231 | 3/20 | 0.56 |
| ▸ | PPARD | Q03181 | 3/20 | 0.56 |
| ▸ | PPARA | Q07869 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | FABP4 | P15090 | 2/20 | 0.56 |
| ▸ | FAAH | O00519 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | F7 | P08709 | 2/20 | 0.56 |
| ▸ | F3 | P13726 | 2/20 | 0.56 |
| ▸ | GMNN | O75496 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL10937214 | 0.97 | FABP3 (0.57) | FABP3TERTPTPN1PPARGPPARD | |
| Hydrochloric Acid SCHEMBL27700912 | 0.90 | FABP3 (0.54) | FABP3TERTPTPN1PPARGPPARD | |
| Hydrochloric Acid SCHEMBL28345403 | 0.89 | CES2 (0.48) | FABP3PTPN1PPARGPPARDPPARA | |
| SCHEMBL28876841 | 0.86 | FABP3 (0.61) | FABP3TERTPTPN1PPARGPPARD | |
| Bromide SCHEMBL27788998 | 0.85 | FABP3 (0.59) | FABP3TERTPTPN1PPARGPPARD | |
| Bromide SCHEMBL2810645 | 0.85 | FABP3 (0.59) | FABP3TERTPTPN1PPARGPPARD | |
| Hydrochloric Acid SCHEMBL29101995 | 0.85 | FABP3 (0.59) | FABP3TERTPTPN1PPARGPPARD | |
| Hydrochloric Acid SCHEMBL25963 | 0.84 | FABP3 (0.62) | FABP3TERTPTPN1PPARGPPARD | |
| Hydrochloric Acid SCHEMBL6940059 | 0.84 | FABP3 (0.62) | FABP3TERTPTPN1PPARGPPARD | |
| Hydrochloric Acid SCHEMBL1029165 | 0.84 | FABP3 (0.62) | FABP3TERTPTPN1PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505942-B1 | PATHOGEN VACCINES AND METHODS FOR USING THE SAME | TEKMIRA PHARMACEUTICALS CORP (CA) | 2008-08-13 | — | — | EP | disclosed |
| EP-1675614-A2 | METHODS AND COMPOSITIONS FOR ENHANCING INNATE IMMUNITY AND ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY | Inex Pharmaceuticals Corp. (CA) | 2006-07-05 | — | — | EP | disclosed |
| US-20050191342-A1 | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity | INEX PHARMACEUTICALS CORPORATION | 2005-09-01 | — | — | US | disclosed |
| WO-2005034979-A2 | METHODS AND COMPOSITIONS FOR ENHANCING INNATE IMMUNITY AND ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY | INEX PHARMACEUTICALS CORPORATION (US) | 2005-04-21 | — | — | WO | disclosed |
| EP-1506010-A2 | METHYLATED IMMUNOSTIMULATORY OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | Inex Pharmaceuticals Corporation (CA) | 2005-02-16 | — | — | EP | disclosed |
| EP-1505942-A2 | PATHOGEN VACCINES AND METHODS FOR USING THE SAME | Inex Pharmaceuticals Corp. (CA) | 2005-02-16 | — | — | EP | disclosed |
| EP-1503793-A2 | CANCER VACCINES AND METHODS OF USING THE SAME | Inex Pharmaceuticals Corp. (CA) | 2005-02-09 | — | — | EP | disclosed |
| EP-1441763-A2 | MUCOSAL ADJUVANTS COMPRISING AN OLIGONUCLEOTIDE AND A CATIONIC LIPID | Inex Pharmaceuticals Corp. (CA) | 2004-08-04 | — | — | EP | disclosed |
| US-20040013649-A1 | Cancer vaccines and methods of using the same | INEX PHARMACEUTICALS CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20040009944-A1 | Methylated immunostimulatory oligonucleotides and methods of using the same | INEX PHARMACEUTICALS CORPORATION | 2004-01-15 | — | — | US | disclosed |
| WO-2003094963-A2 | METHYLATED IMMUNOSTIMULATORY OLIGONUCLEOTIDES AND METHODS OF USING THE SAME | INEX PHARMACEUTICALS CORPORATION (CA) | 2003-11-20 | — | — | WO | disclosed |
| US-20030125292-A1 | Mucoscal vaccine and methods for using the same | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2003-07-03 | — | — | US | disclosed |
| WO-2003039595-A2 | MUCOSAL ADJUVANTS COMPRISING AN OLIGONUCLEOTIDE AND A CATIONIC LIPID | INEX PHARMACEUTICALS CORPORATION (CA) | 2003-05-15 | — | — | WO | disclosed |
| EP-0783296-B1 | NOVEL COMPOSITIONS FOR THE INTRODUCTION OF POLYANIONIC MATERIALS INTO CELLS | INEX PHARMACEUTICALS CORP (CA) | 2002-06-26 | — | — | EP | disclosed |
| US-20020037834-A1 | Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis | INVITROGEN CORPORATION | 2002-03-28 | — | — | US | disclosed |
| EP-1179340-A2 | Compositions for the introduction of polyanionic materials into cells | INEX Pharmaceutical Corp. (CA) | 2002-02-13 | — | — | EP | disclosed |
| US-5785992-A | LIPOSOMES AND CATIONIC COMPOUNDS | INEX PHARMACEUTICALS CORP. (CA) | 1998-07-28 | — | — | US | disclosed |
| US-5753613-A | Compositions for the introduction of polyanionic materials into cells | INEX PHARMACEUTICALS CORPORATION (CA) | 1998-05-19 | — | — | US | disclosed |
| EP-0783296-A1 | NOVEL COMPOSITIONS FOR THE INTRODUCTION OF POLYANIONIC MATERIALS INTO CELLS | INEX Pharmaceutical Corp. (CA) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996010390-A1 | NOVEL COMPOSITIONS FOR THE INTRODUCTION OF POLYANIONIC MATERIALS INTO CELLS | INEX PHARMACEUTICALS CORP. (CA) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050191342-A1 | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity | STING1, MYD88, PRF1 | CHRM1 4334/4885SLC6A2 4441/4885FABP3 3894/4885 |
| US-20040013649-A1 | Cancer vaccines and methods of using the same | CD47, STING1, TAP1 | CHRM1 4815/4885SLC6A2 3909/4885FABP3 1004/4885 |
| US-20020037834-A1 | Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis | POLRMT, POLN, POLI | CHRM1 4860/4885SLC6A2 2239/4885FABP3 4122/4885 |
| US-20040009944-A1 | Methylated immunostimulatory oligonucleotides and methods of using the same | TLR9, TLR3, NSUN2 | CHRM1 2310/4885SLC6A2 3407/4885FABP3 1862/4885 |
| US-20030125292-A1 | Mucoscal vaccine and methods for using the same | MUC1, SIGLEC7, TLR9 | CHRM1 2527/4885SLC6A2 3126/4885FABP3 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.